EU, Japan and other countries for the treatment of certain paediatric patients with NF1 who have symptomatic, inoperable PN. In July 2017, AstraZeneca and Merck & Co., Inc., Rahway, NJ, US, known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback